Belinostat IV days 1-5 q21d (BELIEF schedule) — r/r PTCL incl AITL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-BELINOSTAT |
|---|
| ID | REG-BELINOSTAT-PTCL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Notes
BELIEF trial (O'Connor 2015): r/r PTCL n=129 (incl AITL ~22%, PTCL NOS ~58%, ALCL ~10%, others) — overall ORR 26%, CR 11%, mDOR 13.6 mo, mPFS 1.6 mo (mature responders 13.6 mo). AITL subset response numerically higher than PTCL NOS (small cohort). FDA-approved for r/r PTCL after ≥1 prior line. Key advantage: distinct mechanism from chemo + most targeted agents — useful as bridge or last-line.
Used By
Indication
IND-AITL-2L-BELINOSTAT- IND-AITL-2L-BELINOSTAT